...
首页> 外文期刊>Japanese Journal of Cancer Research >Genetic Polymorphisms of the UDP-Glucuronosyltransferase 1A7 Gene and Irinotecan Toxicity in Japanese Cancer Patients.
【24h】

Genetic Polymorphisms of the UDP-Glucuronosyltransferase 1A7 Gene and Irinotecan Toxicity in Japanese Cancer Patients.

机译:UDP-葡萄糖醛酸转移酶1A7基因的遗传多态性和伊立替康的毒性在日本癌症患者中。

获取原文
获取原文并翻译 | 示例

摘要

Irinotecan often causes unpredictably severe, occasionally fatal, toxicity involving leukopenia or diarrhea. It is converted by carboxyesterase to an active metabolite, SN-38, which is further conjugated and detoxified to SN-38-glucuronide by UDP-glucuronosyltransferase (UGT). We genotyped the UGT1A7 gene by direct sequencing analysis and polymerase chain reaction-restriction fragment length polymorphism in 118 cancer patients and 108 healthy subjects. All the patients had received irinotecan-containing chemotherapy and were evaluated to see whether the variant UGT1A7 genotype would increase the likelihood of severe toxicity of irinotecan consisting of grade 4 leukopenia and / or grade 3 or more diarrhea. Among the 26 patients with severe toxicity, the allele frequencies were 61.5% for UGT1A7 (*)1, 15.4% for UGT1A7 (*)2, and 23.1% for UGT1A7 (*)3. On the other hand, the frequencies were 63.6% for UGT1A7 (*)1, 15.8% for UGT1A7 (*)2, and 20.7% for UGT1A7 (*)3 among the 92 patients without severe toxicity. None of the 118 patients had UGT1A7 (*)4. Neither univariate analysis (odds ratio, 1.13; 95% confidential interval, 0.46 - 2.75) nor multivariate logistic regression analysis (odds ratio, 0.74; 95% confidential interval, 0.26 - 2.07) found any significant association between carrying at least one of the variant alleles and the occurrence of severe toxicity. The distribution of UGT1A7 genotypes in 108 healthy subjects was not significantly different from that in the patients (P = 0.99 and 0.86 for those with and without severe toxicity, respectively), but significantly less than that in Caucasians reported previously (P < 0.001). The results suggested that determination of UGT1A7 genotypes would not be useful for predicting severe toxicity of irinotecan.
机译:伊立替康经常引起涉及白细胞减少症或腹泻的不可预测的严重的,有时是致命的毒性。它被羧基酯酶转化为活性代谢产物SN-38,并通过UDP-葡萄糖醛酸糖基转移酶(UGT)与SN-38-葡萄糖醛酸化物进一步缀合并解毒。我们通过直接测序分析和118位癌症患者和108位健康受试者的聚合酶链反应-限制性片段长度多态性对UGT1A7基因进行了基因分型。所有患者均接受了含伊立替康的化疗,并进行了评估,以查看变异的UGT1A7基因型是否会增加由4级白细胞减少症和/或3级以上腹泻组成的伊立替康发生严重毒性反应的可能性。在26名严重毒性反应患者中,UGT1A7(*)1的等位基因频率为61.5%,UGT1A7(*)2的等位基因频率为15.4%,UGT1A7(*)3的等位基因频率为23.1%。另一方面,在没有严重毒性反应的92例患者中,UGT1A7(*)1的频率为63.6%,UGT1A7(*)2的频率为15.8%,UGT1A7(*)3的频率为20.7%。 118例患者均未患有UGT1A7(*)4。单变量分析(赔率,1.13; 95%机密区间,0.46-2.75)和多元逻辑回归分析(赔率,0.74; 95%机密区间,0.26-2.07)均未发现携带至少一种变体之间存在显着关联等位基因并发生严重毒性反应。 UGT1A7基因型在108名健康受试者中的分布与患者无显着差异(分别为有和没有严重毒性反应的患者分别为P = 0.99和0.86),但显着低于先前报道的高加索人(P <0.001)。结果表明UGT1A7基因型的确定将无法用于预测伊立替康的严重毒性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号